SAN DIEGO, March 14, 2023 – Onchilles Pharma, a private biotech company developing new cancer therapeutics that leverage myeloid biology, announced today the presentation of preclinical data for N17350 at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14 to 19 at the Orange County Convention Center in Orlando,…
SAN DIEGO, December 12, 2022 – Onchilles Pharma, a private biotech company developing new cancer therapeutics to modulate myeloid biology, announced today the nomination of its first drug development candidate, N17350, a first-in-class biologic therapeutic that is designed to leverage the immunobiology of neutrophils, a key part in the innate immune system, against a wide…
– Foundational research published today in Cell is the first to describe ELANE, a major anti-cancer protein released by human neutrophils that activates cell death pathways specifically in cancer cells – ELANE demonstrates broad and selective cancer killing efficacy and attenuation of tumor growth and metastases in multiple preclinical models – Financing will advance the…